<DOC>
	<DOCNO>NCT01556945</DOCNO>
	<brief_summary>The purpose study see two new malaria vaccine call FMP1 RTSS , combine adjuvant ( call SBAS2 ) help stimulate body 's immune system , safe , demonstrate immune response blood test , lastly , see vaccines prevent malaria infection . The RTS , S vaccine contain malaria protein combination portion commercially available hepatitis B vaccine . The FMP1 vaccine also contain malaria protein . The adjuvant call SBAS2 , special oil water emulsion . Vaccinations do study day 0 , 28 84 , follow malaria challenge approximately 14 day 3rd vaccination .</brief_summary>
	<brief_title>Safety Preliminary Efficacy Malaria Vaccine Candidates Falciparum Merozoite Protein-1 ( FMP1 ) SmithKlineBeecham ( SKBB ) Candidate Malaria Vaccine RTS , S</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult , 1845 Available duration study ( 9 month ) Written informed consent prior study procedure Prior receipt investigational malaria vaccine one contain MPL QS21 Use investigational nonregistered drug/vaccine plan administration vaccine foreseen study protocol ; issue within 30 day precede first dose study vaccine Administration chronic immunosuppressant Chronic use antibiotic History malaria ever , use malaria chemoprophylaxis within 60 day prior vaccination Known exposure malaria within past 12 month plan travel malarious area study period Confirmed suspect immunosuppressive immunodeficient condition Family history congenital hereditary immunodeficiency History allergic disease reaction likely exacerbate component vaccine Chronic active neurologic disease include seizure History splenectomy Seropositive hepatitis B hepatitis C Human Immunodeficiency Virus ( HIV ) , abnormal lab significant anemia , elevate creatinine Hepatomegaly , right upper quadrant abdominal pain Pregnant lactate female Chronic active drug alcohol use History severe reaction mosquito bite Any history anaphylaxis vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>P. falciparum</keyword>
	<keyword>vaccine</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>